AMENDMENT No. 2 TO AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 9th, 2016 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 2 to Amended and Restated Development and License Agreement (the “Amendment No. 2”) is made as of this 27th day of September, 2016 (the “Amendment 2 Effective Date”) by and between Intellikine LLC, a limited liability company organized and existing under the laws of the State of Delaware and successor to Intellikine, Inc. (“Intellikine”), and Infinity Pharmaceuticals, Inc., a company organized and existing under the laws of the State of Delaware (“Infinity”). Intellikine and Infinity are each referred to individually as a “Party” and together as the “Parties”.
